Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis

Area of Science:

• Biochemistry
• Cardiovascular Research
• Pharmacology

Background:

• Amphipathic α-helical peptides can functionally mimic apolipoproteins.
• High-density lipoprotein (HDL) plays a role in combating atherosclerosis.
• Apolipoprotein A-I (apoA-I) is a key component of HDL.

Purpose of the Study:

• To summarize key findings and advances in apolipoprotein mimetic peptide development over 25 years.
• To provide an overview of the current state of the art in the apolipoprotein mimetic field.
• To highlight the potential of these agents in pharmacotherapy and HDL optimization.

Main Methods:

• Review and synthesis of research findings over the past 25 years.
• Focus on peptides mimicking apolipoprotein A-I (apoA-I).
• Analysis of functional properties and potential therapeutic applications.

Main Results:

• Significant progress in developing apolipoprotein mimetic peptides.
• Demonstrated ability of these peptides to mimic apoA-I properties.
• Established potential for modulating HDL function.

Conclusions:

• Apolipoprotein mimetic peptides represent a viable approach for HDL modulation.
• These peptides hold promise for pharmacotherapy against atherosclerosis.
• Opportunities exist for optimizing HDL functional properties using these mimetics.